Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Common Equity (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Common Equity for 8 consecutive years, with -$38.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 23.35% to -$38.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$38.5 million through Dec 2025, up 23.35% year-over-year, with the annual reading at -$32.2 million for FY2025, N/A changed from the prior year.
  • Common Equity for Q4 2025 was -$38.5 million at Outlook Therapeutics, down from -$32.2 million in the prior quarter.
  • The five-year high for Common Equity was -$32.2 million in Q3 2025, with the low at -$50.3 million in Q4 2024.